Immune checkpoint inhibitors targeting pathways like PD-1/PD-L1 and CTLA-4 have revolutionized cancer immunotherapy.These pathways regulate T cell responses, and their blockade can restore anti-tumor immunity…
Immune Checkpoint Inhibitors (ICIs) have emerged as a groundbreaking therapeutic modality in the field of oncology, offering new hope for patients with various types of cancer, including gynecological malignancies…
undergoing an oropharyngeal swab for the detection of SARS-CoV-2 infection at any Checkpoint filled the questionnaire on personal data, symptoms, chronic diseases and the reason for the swab ... Checkpoints were created…
cancers. Our study reveals a new genes survival prognostic model from recent Immune checkpoint inhibitors (ICIs) databases for glioma cancer. Methods: The Cancer Genome Atlas TCGA transcriptomic analysis and matching…
cancers. Our study reveals a new genes survival prognostic model from recent Immune checkpoint inhibitors (ICIs) databases for glioma cancer. Methods The Cancer Genome Atlas TCGA transcriptomic analysis and matching…
move differently depending on the binding partner: the natural ligand, PD-L1, or the checkpoint inhibitors nivolumab and pembrolizumab, respectively. Computational analysis was performed by an interdisciplinary team…
Immune Checkpoint Inhibitors induced Myocarditis is a serious adverse event. The clinical manifestation can be quite variable and the classic features of myocarditis are not always found. Although challenging…
tumour mutation burden within solid tumours may be predictive for clinical response to immune checkpoint blockade but can be difficult to assess within routine clinical practice. This presentation discusses…
tumour mutation burden within solid tumours may be predictive for clinical response to immune checkpoint blockade but can be difficult to assess within routine clinical practice. This presentation discusses…
Background: Checkpoint kinase 1 (CHK1) is a serine/threonine-protein kinase which plays a major role during checkpoint-mediated cell cycle arrest and activation of DNA repair in response
cancer. To further augment the immune response, combination therapies of therapeutic vaccines with checkpoint inhibitors such as ipilimumab are currently tested in clinical studies. Ipilimumab is an antibody that blocks…
been a recent hot topic among scientists over the world. So far, the discovered checkpoint protein molecules include cytotoxic T lymphocyte antigen-4 (CTLA-4), programmed death ... lymphocyte activation gene-3 (LAG-3)…
Several monoclonal antibodies (mAbs) against immune checkpoint targets have been approved by the FDA for diagnostic or therapeutic applications in advanced cancer. An increasing number of mAbs has been developed…
domain Ig suppressor of T cell activation (VISTA) is a novel negative checkpoint ligand that suppresses T-cell mediated immune responses. Previous studies using VISTA-neutralizing monoclonal antibody show that…
While anti-PD1/PDL1 immune checkpoint blockade has shown promising clinical success in solid tumors [1,2] its effectiveness in Acute Myeloid Leukemia (AML) remains limited, AML is considered
aggression. But in recent years, a revolutionary approach has emerged—immunotherapy, and more specifically, checkpoint inhibitors. These drugs don’t attack cancer cells directly. Instead, they empower the body
Neurologic adverse events (NAEs) associated with immune checkpoint inhibitors (ICIs) have emerged as significant complications in cancer immunotherapy. While ICIs have revolutionized the treatment of various…
identify and attack cancer cells. There are several types of immuno-oncology agents, including checkpoint inhibitors, CAR-T cell therapy, and cancer vaccines
this disease. In recent years, researchers have begun to investigate the expression of immunomodulatory checkpoint molecules in drug-resistant neuroblastoma cells as a potential target for new therapies
triple negative subtype. There are no current recommendations for the use of checkpoint inhibitors in HER2 positive disease; although the tumor biology in HER2-positive breast cancer demonstrates that
therapy. We enter a domain of highly individualized treatment strategies. Finally, modulatory immunotherapies like checkpoint inhibitors, metronomic cyclophosphamide, metronomic capecitabine, risedronate, total body…
high rate of recurrence and metastases, including regional nodal metastases. The use of checkpoint inhibitors (CPIs) has shown promising results in the treatment of metastatic MCC and, consequently, CPIs
Methods: A multi-institutional phase Ib trial of radiation therapy in combination with immune checkpoint inhibition (anti-CTLA4 alone, anti-PD-L1 alone, or anti-CTLA4 with anti-PDL1
Background: New therapies, including oral multitargeted Tyrosine Kinase Inhibitors (TKIs) and immune checkpoint inhibitors (IO), have significantly increased survival in the majority of patients with metastatic Renal…
For authors and organisers
Publish, present and keep up with your field
Find the right journal for your paper and submit your manuscript.